Search
Researchers at The Kids Research Institute Australia have been awarded $4.6 million in national funding from the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF) to help support child health research.
The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.
In the field of cancer research, lobbying efforts by the The Kids Cancer Centre have contributed to major initiatives including Australia’s first personalised medicine program for children with high-risk cancer, and a mission to boost survival rates in brain cancer patients.
The Kids cancer researcher & clinician Dr Nick Gottardo has been announced as the recipient of an Innovation Grant from the Cure Brain Cancer Foundation.
A The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
Rennae's son Samuel was diagnosed with stage 4 neuroblastoma 13 years ago, and was originally given a 20% chance of survival. She bravely shares their story.
KMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday
Invasive fungal disease is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.
Despite significant advances, outcomes for children with Down syndrome (DS, trisomy 21) who develop acute lymphoblastic leukemia remain poor. Reports of large DS-ALL cohorts have shown that children with DS have inferior event-free survival and overall survival compared to children without DS.